John Lurain is an Oncology physician affiliated with Northwestern University. OpenAlex indexes 259 publications with 12,651 citations (h-index 53). By OpenAlex citation count, this profile ranks in the top 10% of Gynecologic Oncology profiles in the findmyKOL directory.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
680 N Lake Shore Dr
Suite 1000
Chicago, IL 606114546
Telephone
312-695-9797Registry record last updated 8 Jul 2007.
Medicare prescribing footprint (2019)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Metabolism & gastrointestinal
51.3%Other antiemetics47.9%Fosaprepitant100%Part B, office-administered≥25 patientsSerotonin-3 Receptor Antagonist3.4%Palonosetron hcl100%Part B, office-administered≥28 patientsCancer & immunology
44.5%Microtubule Inhibitor42.4%Paclitaxel100%Part B, office-administered≥13 patientsPlatinum-based Drug2%Carboplatin100%Part B, office-administered≥17 patients+ 1 more class in this area
Sensory organs
4.1%Corticosteroid4.1%Dexamethasone sodium phosphate100%Part B, office-administered≥31 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Diagnosis and management of gestational trophoblastic disease: 2021 update
International Journal of Gynecology & Obstetrics
2021 - NCCN Guidelines Insights: Cervical Cancer, Version 1.2020
Journal of the National Comprehensive Cancer Network
2020 - Cervical Cancer, Version 3.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2019 - Gestational Trophoblastic Neoplasia, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2019 - Uterine Neoplasms, Version 1.2018, NCCN Clinical Practice Guidelines in Oncology
Journal of the National Comprehensive Cancer Network
2018
Similar KOLs
Other experts from the same institution or the same specialty.
Clyde Yancy, MD
Northwestern University
Philip Greenland, MD
Northwestern University
Peter Kahrilas, MD
Northwestern University
Philip Gorelick, MD
Northwestern University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”